10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Design of Photosensitizing Agents for Targeted Antimicrobial Photodynamic Therapy

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Photodynamic inactivation of microorganisms has gained substantial attention due to its unique mode of action, in which pathogens are unable to generate resistance, and due to the fact that it can be applied in a minimally invasive manner. In photodynamic therapy (PDT), a non-toxic photosensitizer (PS) is activated by a specific wavelength of light and generates highly cytotoxic reactive oxygen species (ROS) such as superoxide (O 2−, type-I mechanism) or singlet oxygen ( 1O 2*, type-II mechanism). Although it offers many advantages over conventional treatment methods, ROS-mediated microbial killing is often faced with the issues of accessibility, poor selectivity and off-target damage. Thus, several strategies have been employed to develop target-specific antimicrobial PDT (aPDT). This includes conjugation of known PS building-blocks to either non-specific cationic moieties or target-specific antibiotics and antimicrobial peptides, or combining them with targeting nanomaterials. In this review, we summarise these general strategies and related challenges, and highlight recent developments in targeted aPDT.

          Related collections

          Most cited references178

          • Record: found
          • Abstract: found
          • Article: not found

          The antibiotic resistance crisis: part 1: causes and threats.

          Decades after the first patients were treated with antibiotics, bacterial infections have again become a threat because of the rapid emergence of resistant bacteria-a crisis attributed to abuse of these medications and a lack of new drug development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Photodynamic therapy for cancer.

            The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed. At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin. How does PDT work, and how can it be used to treat cancer and other diseases?
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Photodynamic therapy of cancer: An update

              Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                10 November 2020
                November 2020
                : 25
                : 22
                : 5239
                Affiliations
                [1 ]School of Chemistry and the EPSRC IRC Proteus, University of Edinburgh, Joseph Black Building, David Brewster Road, Edinburgh EH9 3FJ, UK; Mark.Bradley@ 123456ed.ac.uk
                [2 ]Department of Analytical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir 35620, Turkey
                Author notes
                [* ]Correspondence: mklausen@ 123456ed.ac.uk (M.K.); muhammed.ucuncu@ 123456ikc.edu.tr (M.U.); Tel.: +44-(0)131-650-4820 (M.K.)
                Author information
                https://orcid.org/0000-0003-0805-9886
                https://orcid.org/0000-0001-6200-9340
                Article
                molecules-25-05239
                10.3390/molecules25225239
                7696090
                33182751
                d3ba822d-472b-464b-a75f-5796f44db906
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 21 October 2020
                : 05 November 2020
                Categories
                Review

                photodynamic therapy,photosensitizer,reactive oxygen species,antimicrobial resistance,nanomaterials,antimicrobial peptides

                Comments

                Comment on this article